{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Glucose, No Change/Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Glucose, Any Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Ketones, No Change/Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Ketones, Any Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Occult Blood, No Change/Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Occult Blood, Any Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Protein, No Change/Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Protein, Any Increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Urine samples were collected to assess urine glucose, protein, occult blood and ketones using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for uranalysis parameters were recorded as no change/decreased and any increase. Data for worst-case post baseline are presented.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results","type":"SECONDARY","unitOfMeasure":"Participants"}